Is the price fair?
What MNKD's price assumes
MannKind Corporation did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 2.09× revenue.
2.09
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 1.1%
Free cash flow yield · Biotechnology median 2.5%
- Growth the price implies
- +26%
Growth the price implies · The price pays for +26% free cash flow growth a year for a decade; revenue has grown +41% a year over the last three.
- EV / sales
- 2.83
EV / sales
Details›
- EV / EBIT2026-Q1
- 68.8
- EV / sales2026-Q1
- 2.83
- Free cash flow, trailing twelve months
- $13M
- Market capitalisation
- $1.22B
- 3-year revenue growth
- +41%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.